Although previous studies have been somewhat inconsistent, a new study shows that breast cancer patients taking tamoxifen who have genetic alterations in CYP2D6 have a higher likelihood of both ...
Accurate prediction of CYP2D6 activity from genotype data is of utmost importance as CYP2D6 pharmacogenetic (PGx) testing is increasingly used to guide drug therapy. However, given the complexity of ...
In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, ...
Cytochrome P450 2D6 (CYP2D6) has a crucial role in the metabolic conversion of tamoxifen into the active metabolite endoxifen. In this cohort study, the effect of CYP2D6-predicted phenotype, defined ...
Recent advances in oligonucleotide microarray technology (“gene chips”) permit rapid screening for DNA sequence variation. The CYP2D6 gene encodes debrisoquine hydroxylase, which metabolizes the ...
Credit: Shutterstock. According to HF guidelines, beta-blockers must be titrated to a specific target dose in order to obtain their morbidity and mortality benefit in HF patients. According to a ...
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical ...
February 9, 2009 — In clinical practice, there is a "hesitation" about testing for CYP2D6 before prescribing tamoxifen to reduce the risk for breast cancer recurrence, observes an editorial published ...
—New research uncovers a possible link between CYP2D6 activity and the development of tardive dyskinesia in certain patients taking antipsychotics. Reviewed by Nicole Foubister, Clinical Assistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback